We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Cancers After Solid Organs Transplants (K-GREF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00948883
Recruitment Status : Completed
First Posted : July 29, 2009
Last Update Posted : April 4, 2013
Sponsor:
Collaborator:
CANCEROPOLE Ile-de-France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

About 1500 solid organs transplants are performed each year in the Paris agglomeration.

Cancer risk in the transplanted is about three times higher than in a population of the same age without any organ transplant. Thus cancer is an important problem for organ transplant.

These cancers can be related to many factors :

  • Post-transplant cancers are due in part to the non specific immunosuppression, which leads to oncogenic viruses replication, and then produces virus inducted cancers (as lymphoma due to EBV virus).
  • Post-transplant cancers can also be due to the carcinogenic factors of the immunosuppressive drugs (as cyclosporine or tacrolimus, which can cause the appearance of metastases). However, a new type of immunosuppressive drugs (mTOR inhibitors) appear to have anti-cancer properties.
  • Post-transplant cancers which are not virus-inducted can be relied to genetic factors of the transplanted patient and/or the transplant donor.

There are 4 axes in this study :

  • Axis 1 : Epidemiological, clinical and biological study of the incident cancers in transplanted patients.
  • Axis 2 : Qualitative and quantitative immunological study of lymphocyte cells by the transplanted patient (determine their characteristics when a cancer appears).
  • Axis 3 : Pathological and genetic study of the post-transplant cancer cells (see if the cancer is caused by the donor or the recipient). Creation of a biobank.
  • Axis 4 : Pharmacogenetic study of the immunosuppressive drugs (determine the impact of patient genetic variability on tolerance and efficiency of the immunosuppressive drugs).

Condition or disease
Cancer Organ Transplantation

Detailed Description:

This is an observational and comparative study (2 control patients are recruited for each 1 case patient).

A case patient is a patient who has developed a cancer after his/her transplant.

A control patient is a patient who has not developed a cancer after his/her transplant.

These 2 groups will be matched according to specific inclusion criteria.


Study Type : Observational
Actual Enrollment : 330 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Epidemiological, Immunological, Pathological and Pharmacogenetic Study of Cancers Occuring After Solid Organs Transplants
Study Start Date : October 2008
Primary Completion Date : July 2011
Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
Patient-Case
Transplanted patient with cancer
Patient-Control
Transplanted patient without cancer



Primary Outcome Measures :
  1. Incidence of cancer among transplanted patients. [ Time Frame: At the day of blood collection ]

Secondary Outcome Measures :
  1. Characteristics of the tumors. [ Time Frame: At the day of blood collection ]
  2. Risk factors of the tumors. [ Time Frame: At the day of blood collection ]

Biospecimen Retention:   Samples With DNA
Whole blood, frozen tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with solid organ transplant who have developed a cancer. Patients with solid organ transplant who have not developed a cancer.
Criteria

Inclusion Criteria:

  • Man or woman after 18 years old
  • Transplanted with a solid organ (heart, kidney, lung,liver)
  • Informed Consent Form signed
  • For the patients-case: Patients who developed a post-transplant cancer
  • For the patients-control: Patients who didn't develop a post-transplant cancer

Exclusion Criteria:

  • Cancer as transplant indication ( except liver )
  • HIV positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00948883


Locations
France
Hôpital Bicêtre - Assistance Publique-Hôpitaux de Paris
Le Kremlin Bicetre Cedex, France, 94275
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
CANCEROPOLE Ile-de-France
Investigators
Principal Investigator: Michel MARTY, MD Assistance Publique - Hôpitaux de Paris

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00948883     History of Changes
Other Study ID Numbers: DRCD CANC 0701
First Posted: July 29, 2009    Key Record Dates
Last Update Posted: April 4, 2013
Last Verified: April 2013

Keywords provided by Assistance Publique - Hôpitaux de Paris:
organ transplant
cancer
biobank
immunosuppressive drugs
lymphoma